|
|
|
|
|
Highlights from the 2023 ASCO Genitourinary Cancers Symposium
|
|
|
|
|
|
Oral Abstracts: Prostate Cancer
|
|
| Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence Prognostic Biomarker in High-Risk Prostate Cancer: Results from Six NRG/RTOG Phase III Randomized Trials
|
| Daniel E. Spratt, MD
|
| Daniel Spratt discussed a patient-level data meta-analysis of a multi-modal artificial intelligence prognostic biomarker in high-risk prostate cancer. Recently, a multi-modal artificial intelligence prognostic biomarker, Artera AI Prostate, was trained and validated in localized prostate cancer to more accurately risk stratify patients for multiple endpoints compared to NCCN risk groups.
|
|
|
|
|
|
| FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy and 6 Months of GnRH Agonist with or Without Abiraterone Acetate/prednisone and Apalutamide Post-Radical Prostatectomy
|
| Paul L. Nguyen, MD
|
| The 2023 GU ASCO annual meeting included an oral abstract prostate cancer session, featuring a presentation by Dr. Paul Nguyen discussing results of the FORMULA-509 trial, a multicenter randomized trial of post-operative salvage radiotherapy and 6 months of GnRH agonist with or without abiraterone acetate/prednisone and apalutamide post-radical prostatectomy.
|
|
|
|
|
|
| Discussion of Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence Prognostic Biomarker and the FORMULA-509 Trial of Post-Operative Salvage Radiotherapy Post-Radical Prostatectomy
|
| Tyler Seibert, MD, Ph.D.
|
| Tyler Seibert discussed, “Patient-level data meta-analysis of a multi-modal artificial intelligence prognostic biomarker in high-risk prostate cancer: Results from six NRG/RTOG phase III randomized trials”, and “FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy and 6 months of GnRH agonist with or without abiraterone acetate/prednisone and apalutamide post-radical prostatectomy”.
|
|
|
|
|
|
|
|
|
|
|
| Trials in Progress Poster Session A: Prostate Cancer |
| The CONFIDENT-P Trial: Clinical Implementation of Artificial Intelligence Assistance in Prostate Cancer Pathology |
| Rachel Flach, MD
|
| Rachel Flach presented the framework for the CONFIDENT-P trial, which will evaluate the clinical implementation of artificial intelligence assistance in prostate cancer pathology.
|
|
|
|
|
|
| Poster Session A: Prostate Cancer |
| Time Interval Between Radium‑223 (223Ra) Therapy and Lutetium-177–prostate-Specific Membrane Antigen (177Lu-PSMA) Treatment and Outcomes in the RALU Study
|
| Kambiz Rahbar, MD
|
| Kambiz Rahbar presented data from the RALU trial examining the association between the time interval between sequential treatment with radium‑223 (223Ra) therapy and Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) and subsequent outcomes.
|
|
|
|
|
|
| Efficacy of Systemic Therapy Following [177Lu] Lu-PSMA in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
| Arun Azad, PhD, MBBS, FRACP
|
| Arun Azad presented data examining the efficacy of subsequent systemic therapies after Lu177 radioligand therapy for patients with metastatic castration-resistant prostate cancer. |
|
|
|
|
|
| Initial Results of a Phase 2 Pilot Study of Radium-223 and Radiotherapy in Untreated Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone
|
| Jonathan David Tward, MD, Ph.D.
|
| Jonathan Tward presented on a novel approach to treatment of patients with hormone-naïve, oligometastatic prostate cancer to bone with a combination of radium-223 and radiotherapy. |
|
|
|
|
|
| Activity of Lutetium-177 PSMA (Lu-PSMA) and Determinants of Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Cabazitaxel: The PACAP Study
|
| Ronan Flippot, MD
|
| Ronan Flippot presented on the efficacy of lutetium-177 PSMA (Lu-PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel.
|
|
|
|
|
|
|
|
|
|
|
| Evaluation of a Novel Transcriptomic Tumor Signature (PROSTest) as Response Biomarker for 177Lu-PSMA Therapy in Advanced Prostate Cancer
|
| Alin Chirindel, MD
|
| Alin Chirindel presented on the evaluation of a novel biomarker for response to lutetium-177 PSMA (Lu-PSMA) advanced prostate cancer. |
|
|
|
|
|
| Racial Differences in Survival and Healthcare Resource Utilization Among Medicaid-Insured Adults with Metastatic Castration-Sensitive Prostate Cancer
|
| Stephen J. Freedland, MD
|
| Stephen Freedland presented data examining racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration sensitive prostate cancer.
|
|
|
|
|
|
| Circulating Tumor DNA Analysis of IMbassador250: Association of ctDNA Fraction, AR Alterations and Therapy Outcome in mCRPC
|
| Christopher Sweeney, MBBS
|
| Christopher Sweeney presented an analysis of the IMbassador250 trial of the association between ctDNA fraction and androgen receptor alterations with therapeutic outcomes.
|
|
|
|
|
|
|
